REFINE-ALS

The purpose of this study is to identify biomarkers to serve as quantifiable measures of Edaravone effects in ALS in those who are initiating clinically prescribed Edaravone treatment for the first time or within one month of consenting. Participants in the study will be followed from enrollment up to 24 weeks after treatment initiation (i.e. 6 treatment cycles).

Principal Investigator: Shafeeq Ladha, MD

Enrollment Contact:

Nicole Turcotte
(602) 406-4775
Fulton.Research@dignityhealth.org